CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

CorMedix Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$7.38+0.12 (+1.65%)

Close on Oct 19, 2026

Market cap: $682.50M
P/E (TTM): 3.6
Dividend yield: –

Dividends

CorMedix has not reported a dividend

No dividend per share appears in CorMedix's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in CorMedix's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Mar 26, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CRMD.

Revenue growth280.5% · median 36.3%

Gross margin82.8% · median 88.2%

Operating margin47.0% · median 10.9%

Net margin40.5% · median -5.1%

Company	Revenue	Growth
KNSA	$840.85M	+58.9%
CRMD	$462.25M	+280.5%
LQDA	$450.91M	+2233.6%
ARDX	$450.89M	+16.8%
XERS	$335.41M	+36.3%
AKBA	$219.06M	+7.5%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 191
Held by institutions: 56.5%
Auditor: CBIZ CPAs P.C
SEC CIK: 1410098

Advertisement
300 × 250